Organon & vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Organon & Co (OGN)

Q2 202617 Jun – 1 Jul 2026

▲2▼2

Organon's $11.75B Sun Pharma takeover, new product deals, and weak Q1 revenue

Sun Pharma's $11.75B takeover of Organon Sun Pharmaceutical is acquiring Organon for $14.00 per share in cash, a deal valued at $11.75 billion. This provides a premium to shareholders and is the main reason OGN is moving. The deal is part of a broader M&A surge in biopharma.
This is the biggest driver of OGN's price, as it sets a floor and provides a clear exit for shareholders.
Investigation into Organon board over merger Brodsky & Smith is investigating Organon's board for potential fiduciary duty breaches in the merger agreement. This could delay the deal or reduce the consideration shareholders receive, creating uncertainty and potential downside for OGN.
This is a new risk that could affect the deal's completion or terms, directly impacting OGN's price.
Organon licenses MIUDELLA, a hormone-free IUD Organon secured exclusive global rights to MIUDELLA, the first new hormone-free copper IUD in over 40 years. This expands Organon's contraception portfolio and addresses unmet demand for non-hormonal options, supporting future revenue growth.
This is a new product addition that strengthens Organon's core business and long-term growth prospects.
Organon Q1 revenue fell 3.5%, missing estimates Organon reported Q1 revenue of $1.46 billion, down 3.5% and below expectations. This weak operational performance contrasts with the takeover premium and highlights challenges in the core business, which could weigh on the stock if the deal falls through.
This is new financial data showing underlying weakness, a counterweight to the positive deal news.

June 202617 Jun – 1 Jul 2026

▲2▼2

Organon's $11.75B Sun Pharma takeover, new product deals, and weak Q1 revenue

Sun Pharma's $11.75B takeover of Organon Sun Pharmaceutical is acquiring Organon for $14.00 per share in cash, a deal valued at $11.75 billion. This provides a premium to shareholders and is the main reason OGN is moving. The deal is part of a broader M&A surge in biopharma.
This is the biggest driver of OGN's price, as it sets a floor and provides a clear exit for shareholders.
Investigation into Organon board over merger Brodsky & Smith is investigating Organon's board for potential fiduciary duty breaches in the merger agreement. This could delay the deal or reduce the consideration shareholders receive, creating uncertainty and potential downside for OGN.
This is a new risk that could affect the deal's completion or terms, directly impacting OGN's price.
Organon licenses MIUDELLA, a hormone-free IUD Organon secured exclusive global rights to MIUDELLA, the first new hormone-free copper IUD in over 40 years. This expands Organon's contraception portfolio and addresses unmet demand for non-hormonal options, supporting future revenue growth.
This is a new product addition that strengthens Organon's core business and long-term growth prospects.
Organon Q1 revenue fell 3.5%, missing estimates Organon reported Q1 revenue of $1.46 billion, down 3.5% and below expectations. This weak operational performance contrasts with the takeover premium and highlights challenges in the core business, which could weigh on the stock if the deal falls through.
This is new financial data showing underlying weakness, a counterweight to the positive deal news.

Latest17 Jun – 1 Jul 2026

▲2▼2

Organon's $11.75B Sun Pharma takeover, new product deals, and weak Q1 revenue

Sun Pharma's $11.75B takeover of Organon Sun Pharmaceutical is acquiring Organon for $14.00 per share in cash, a deal valued at $11.75 billion. This provides a premium to shareholders and is the main reason OGN is moving. The deal is part of a broader M&A surge in biopharma.
This is the biggest driver of OGN's price, as it sets a floor and provides a clear exit for shareholders.
Investigation into Organon board over merger Brodsky & Smith is investigating Organon's board for potential fiduciary duty breaches in the merger agreement. This could delay the deal or reduce the consideration shareholders receive, creating uncertainty and potential downside for OGN.
This is a new risk that could affect the deal's completion or terms, directly impacting OGN's price.
Organon licenses MIUDELLA, a hormone-free IUD Organon secured exclusive global rights to MIUDELLA, the first new hormone-free copper IUD in over 40 years. This expands Organon's contraception portfolio and addresses unmet demand for non-hormonal options, supporting future revenue growth.
This is a new product addition that strengthens Organon's core business and long-term growth prospects.
Organon Q1 revenue fell 3.5%, missing estimates Organon reported Q1 revenue of $1.46 billion, down 3.5% and below expectations. This weak operational performance contrasts with the takeover premium and highlights challenges in the core business, which could weigh on the stock if the deal falls through.
This is new financial data showing underlying weakness, a counterweight to the positive deal news.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.